Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | TTBK1 | Q5TCY1 | 10/20 | 0.57 |
| ▸ | TTBK2 | Q6IQ55 | 10/20 | 0.57 |
| ▸ | AKT1 | P31749 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8929628 | 0.99 | EGFR (0.58) | EGFRTTBK1TTBK2AKT1AURKA | |
| SCHEMBL8929386 | 0.97 | EGFR (0.62) | EGFRTTBK1TTBK2AKT1AURKA | |
| SCHEMBL8929866 | 0.81 | EGFR (0.51) | EGFRTTBK1TTBK2AKT1AURKA | |
| Hydrochloric Acid SCHEMBL8929855 | 0.81 | EGFR (0.50) | EGFRTTBK1TTBK2AKT1AURKA | |
| SCHEMBL27460612 | 0.75 | TTBK1 (0.69) | EGFRTTBK1TTBK2AKT1AURKA | |
| SCHEMBL8929392 | 0.74 | EGFR (0.58) | EGFRTTBK1TTBK2AURKAAURKB | |
| SCHEMBL8929209 | 0.74 | EGFR (0.63) | EGFRTTBK1TTBK2AURKAAURKB | |
| Hydrochloric Acid SCHEMBL8929775 | 0.73 | EGFR (0.57) | EGFRTTBK1TTBK2AURKAAURKB | |
| Hydrochloric Acid SCHEMBL8928980 | 0.73 | EGFR (0.62) | EGFRTTBK1TTBK2AURKAAURKB | |
| SCHEMBL14467210 | 0.72 | EGFR (0.54) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| EP-0795556-A1 | 4-Substituted pyrrolopyrimidine compounds as tyrosin kinase inhibitors | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-09-17 | — | — | EP | claimed |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-0795556-A1 | 4-Substituted pyrrolopyrimidine compounds as tyrosin kinase inhibitors | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | EGFR 1259/4885TTBK1 2062/4885TTBK2 1479/4885 |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | EGFR 2964/4885TTBK1 2633/4885TTBK2 2900/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | EGFR 3860/4885TTBK1 2093/4885TTBK2 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.